252 related articles for article (PubMed ID: 23740422)
1. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.
Farahmand P; Marin F; Hawkins F; Möricke R; Ringe JD; Glüer CC; Papaioannou N; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Peña J; Graeff C; Kapetanos G; Petto H; Gentzel A; Reisinger A; Zysset PK
Osteoporos Int; 2013 Dec; 24(12):2971-81. PubMed ID: 23740422
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
Glüer CC; Marin F; Ringe JD; Hawkins F; Möricke R; Papaioannu N; Farahmand P; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Kapetanos G; Peña J; Graeff C; Petto H; Sanz B; Reisinger A; Zysset PK
J Bone Miner Res; 2013 Jun; 28(6):1355-68. PubMed ID: 23322362
[TBL] [Abstract][Full Text] [Related]
3. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
4. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Blumsohn A; Marin F; Nickelsen T; Brixen K; Sigurdsson G; González de la Vera J; Boonen S; Liu-Léage S; Barker C; Eastell R;
Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
[TBL] [Abstract][Full Text] [Related]
5. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Eastell R; Chen P; Saag KG; Burshell AL; Wong M; Warner MR; Krege JH
Bone; 2010 Apr; 46(4):929-34. PubMed ID: 20060078
[TBL] [Abstract][Full Text] [Related]
6. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
7. An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Nakamura T; Kono T; Sudo A
Osteoporos Int; 2014 Jan; 25(1):377-84. PubMed ID: 23812597
[TBL] [Abstract][Full Text] [Related]
8. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
9. Analysis of daily teriparatide treatment for osteoporosis in men.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
[TBL] [Abstract][Full Text] [Related]
11. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
12. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
13. Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation.
Yamamoto T; Tsujimoto M; Sowa H
Clin Interv Aging; 2015; 10():1101-9. PubMed ID: 26185429
[TBL] [Abstract][Full Text] [Related]
14. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
[TBL] [Abstract][Full Text] [Related]
15. PINP as a biological response marker during teriparatide treatment for osteoporosis.
Krege JH; Lane NE; Harris JM; Miller PD
Osteoporos Int; 2014 Sep; 25(9):2159-71. PubMed ID: 24599274
[TBL] [Abstract][Full Text] [Related]
16. PINP as an aid for monitoring patients treated with teriparatide.
Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
[TBL] [Abstract][Full Text] [Related]
17. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
Gossiel F; Scott JR; Paggiosi MA; Naylor KE; McCloskey EV; Peel NFA; Walsh JS; Eastell R
J Clin Endocrinol Metab; 2018 Apr; 103(4):1302-1309. PubMed ID: 29365099
[TBL] [Abstract][Full Text] [Related]
18. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
[TBL] [Abstract][Full Text] [Related]
19. Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
Fahrleitner-Pammer A; Burr D; Dobnig H; Stepan JJ; Petto H; Li J; Krege JH; Pavo I
Bone; 2016 Aug; 89():16-24. PubMed ID: 27185100
[TBL] [Abstract][Full Text] [Related]
20. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]